S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Ironwood Pharmaceuticals Announces Initiation of Phase II Trial of Linaclotide in Adult Patients with Opioid-Induced Constipation|
|Synergy Pharmaceuticals Announces Positive Results of SP-333 Phase 2 Trial in Patients with Opioid-Induced Constipation|
|FDA Approves MOVANTIK™ (naloxegol) Tablets C-II for the Treatment of Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain|
|Progenics Receives $40 Million Milestone Following FDA Approval of RELISTOR for OIC Patients With Chronic Non-Cancer Pain|
|FDA Approves RELISTOR® Subcutaneous Injection for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-cancer Pain|
|Progenics Pharmaceuticals Announces Third Quarter 2014 Financial Results|
|Sucampo Announces Third Quarter 2014 Financial Results|
|Nektar Therapeutics Announces MOVENTIG® (naloxegol) Receives Positive CHMP Opinion In EU For Treatment Of Adults With Opioid-Induced Constipation|
|Sucampo and Takeda Launch Direct-to-Consumer Advertising Campaign for AMITIZA(R) (lubiprostone) for Chronic Idiopathic Constipation|
|Clinical Data for AMITIZA(R) Lubiprostone to be Presented at the American College of Gastroenterology 2014 Annual Scientific Meeting|
Click above to view more mutual fund data and stats for oic - Opus International Consultants Ltd.